The invention provides one or more miRNAs, including but not limited miR-103, miR-30d, and miR-30e, for predicting the response of cancer cells to glucorticoids treatment. The invention further provides therapeutic uses of said miRNA molecules for increasing cells sensitivity to glucorticoids induced cell apoptosis.